ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

COVID-19 and chronic kidney disease: peculiarities of treatment

Journal: Ukrainian Journal of Nephrology and Dialysis (Vol.2, No. 74)

Publication Date:

Authors : ; ;

Page : 83-89

Keywords : chronic kidney disease; COVID-19; statins; angiotensin-converting enzyme inhibitors;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

The present study aimed to characterize the management of patients with chronic kidney disease with concomitant COVID-19. Articles published in 2019-2021 in the PubMed, Scopus, and Google Scholar electronic databases were analyzed. As a result of this review, the following particularities of COVID-19 treatment in chronic kidney disease could be summarized. It is obligatory to continue treatment with renin-angiotensin-aldosterone system inhibitors in patients with chronic kidney disease and COVID-19. Lisinopril is considered used for avoiding the elevated renal expression of angiotensin-converting enzyme 2. Spironolactone can prevent acute lung injuries and is reasonable if the triple combination of drugs for reducing blood pressure is not effective. Low-dose rosuvastatin therapy is recommended for patients with COVID-19 and chronic kidney disease stages 3-5 treated with antiretroviral drugs such as lopinavir and ritonavir, remdesivir. Ezetimibe is reasonable to use in case of ineffective higher doses of statins and to decrease hospitalization risk.

Last modified: 2022-12-22 21:02:20